Biliary neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Biliary neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer https://clinicaltrials.eu/trial/study-of-mp0317-with-durvalumab-gemcitabine-and-cisplatin-combination-therapy-as-first-line-treatment-for-patients-with-advanced-biliary-tract-cancer/ Thu, 30 Apr 2026 13:08:06 +0000 https://clinicaltrials.eu/trial/study-of-mp0317-with-durvalumab-gemcitabine-and-cisplatin-combination-therapy-as-first-line-treatment-for-patients-with-advanced-biliary-tract-cancer/ This clinical trial focuses on treating patients with Advanced Biliary Tract Carcinoma, a type of cancer that affects the bile ducts. The study evaluates a new treatment approach combining several medications: MP0317 (an experimental drug), durvalumab (an immunotherapy medication), and two chemotherapy drugs – gemcitabine and cisplatin.

The purpose of this study is to determine how well this combination therapy works in patients who have not previously received treatment for their advanced bile duct cancer. The treatment involves giving the medications through intravenous infusions, which means they are delivered directly into the bloodstream through a vein.

During the study, patients will receive treatment over several months. The doctors will monitor how the cancer responds to the treatment using imaging scans. They will also track any side effects that may occur and evaluate how the treatment affects patients’ quality of life. The study will measure how long patients live without their cancer getting worse and their overall survival time.

]]> Study of AZD4360 safety and effectiveness in adults with advanced solid tumors including gastric, gastroesophageal junction, biliary tract cancer and pancreatic cancer https://clinicaltrials.eu/trial/study-of-azd4360-safety-and-effectiveness-in-adults-with-advanced-solid-tumors-including-gastric-gastroesophageal-junction-biliary-tract-cancer-and-pancreatic-cancer/ Wed, 29 Apr 2026 15:06:33 +0000 https://clinicaltrials.eu/trial/study-of-azd4360-safety-and-effectiveness-in-adults-with-advanced-solid-tumors-including-gastric-gastroesophageal-junction-biliary-tract-cancer-and-pancreatic-cancer/ This study focuses on patients with advanced solid tumors, specifically gastric cancer, gastroesophageal junction cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma. These are types of cancer that have spread or cannot be removed by surgery. The study will test a new medication called AZD4360, which is an antibody drug conjugate given through an intravenous infusion (delivered directly into a vein).

The purpose of this research is to understand how safe AZD4360 is and how well it works in treating these types of cancer. The study will also examine how the medication moves through the body over time. The medication will be given to patients whose cancer has a specific characteristic called CLDN18.2 expression and who have already received at least one previous treatment for their cancer.

This is a combined Phase 1 and Phase 2 study, which means it will first determine the safest dose of the medication and then test how effective it is at treating these cancers. During the study, participants will receive AZD4360 and undergo various medical assessments to monitor their health and the medication’s effects. The treatment will continue as long as patients are benefiting from it and not experiencing unacceptable side effects.

]]> Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-on-ifinatamab-deruxtecan-for-patients-with-recurrent-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 15:02:04 +0000 https://clinicaltrials.eu/trial/study-on-ifinatamab-deruxtecan-for-patients-with-recurrent-or-metastatic-solid-tumors/ This clinical trial is focused on studying the effects of a new treatment called Ifinatamab deruxtecan, also known by its code name DS-7300a. This treatment is being tested on various types of cancers that have either come back or spread to other parts of the body. These cancers include endometrial cancer, head and neck squamous cell carcinoma, pancreatic cancer, colorectal cancer, liver cancer, esophageal and stomach cancer, bladder cancer, ovarian cancer, cervical cancer, biliary tract cancer, HER2-low breast cancer, HER2 IHC 0 breast cancer, and cutaneous melanoma. The purpose of the study is to evaluate how effective and safe Ifinatamab deruxtecan is for patients with these types of cancers.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

]]> Study on AZD0901 and Drug Combination for Patients with Advanced Gastric, Gastroesophageal, and Pancreatic Cancers Expressing Claudin 18.2 https://clinicaltrials.eu/trial/study-on-azd0901-and-drug-combination-for-patients-with-advanced-gastric-gastroesophageal-and-pancreatic-cancers-expressing-claudin-18-2/ Wed, 29 Apr 2026 14:59:47 +0000 https://clinicaltrials.eu/trial/study-on-azd0901-and-drug-combination-for-patients-with-advanced-gastric-gastroesophageal-and-pancreatic-cancers-expressing-claudin-18-2/ This clinical trial is focused on studying advanced forms of certain cancers, specifically Gastric Cancer, Gastroesophageal Junction Cancer, and Pancreatic Ductal Adenocarcinoma. The trial will explore the effects of a new treatment called AZD0901, which is being tested both on its own and in combination with other anti-cancer medications. These medications include Onivyde (containing irinotecan), Bendafolin (containing folinic acid), Gemcitabin HEXAL (containing gemcitabine), and Benda-5 FU (containing fluorouracil). The purpose of the study is to investigate the safety and tolerability of AZD0901 and to evaluate its preliminary anti-tumor activity in patients with advanced or metastatic solid tumors that express a protein called Claudin 18.2.

Participants in the study will receive treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the participants over time to assess how well they tolerate the treatment and to observe any changes in their cancer. The trial will also look at how the body processes AZD0901 and whether the immune system reacts to it. The study aims to gather information on the overall survival of participants, how long they live without the cancer getting worse, and how long any positive response to the treatment lasts.

Throughout the study, researchers will collect data on the size of the tumors and any changes that occur. They will also investigate the relationship between certain genetic or protein markers in the tumors and the effectiveness of the treatment. This information will help determine if AZD0901 could be a beneficial treatment option for patients with these types of cancers. The study is expected to continue until 2027, with recruitment of participants starting in late 2024.

]]> Study on Rilvegostomig and Chemotherapy for Patients with Biliary Tract Cancer After Surgery https://clinicaltrials.eu/trial/study-on-rilvegostomig-and-chemotherapy-for-patients-with-biliary-tract-cancer-after-surgery/ Wed, 29 Apr 2026 14:29:43 +0000 https://clinicaltrials.eu/trial/study-on-rilvegostomig-and-chemotherapy-for-patients-with-biliary-tract-cancer-after-surgery/ This clinical trial is focused on studying the effects of a new treatment for biliary tract cancer, which includes types like intrahepatic or extrahepatic cholangiocarcinoma and muscle invasive gallbladder cancer. The treatment being tested is called rilvegostomig, also known by its code name AZD2936. It is a type of protein treatment given through an infusion, which means it is delivered directly into the bloodstream. The study will also involve the use of various chemotherapy drugs, including gemcitabine, capecitabine, cisplatin, and tegafur, which are commonly used to treat cancer. These drugs will be given either by infusion or orally, depending on the specific medication.

The purpose of this study is to determine if rilvegostomig, when combined with chemotherapy, is safe and effective in delaying the return of cancer after surgery. Participants in the study will be randomly assigned to receive either the new treatment combination or a placebo with chemotherapy. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. The study will take place over several months, with regular check-ups and assessments to monitor the participants’ health and the progression of the disease.

Throughout the study, the main focus will be on measuring how long participants remain free from cancer recurrence, known as recurrence-free survival. Other important aspects being evaluated include overall survival, which is the length of time participants live after treatment, and how well participants tolerate the treatment. The study aims to provide valuable information on whether rilvegostomig can be a beneficial addition to the current treatment options for biliary tract cancer.

]]> Study on the Safety and Effectiveness of MK-2870 Alone or with Other Drugs for Patients with Colorectal, Pancreatic, and Biliary Tract Cancers https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mk-2870-alone-or-with-other-drugs-for-patients-with-colorectal-pancreatic-and-biliary-tract-cancers/ Wed, 29 Apr 2026 14:27:36 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mk-2870-alone-or-with-other-drugs-for-patients-with-colorectal-pancreatic-and-biliary-tract-cancers/ This clinical trial is focused on studying certain types of gastrointestinal cancers, specifically colorectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer. The study will evaluate a new treatment called MK-2870, which is a type of medication known as a humanised IgG1 monoclonal antibody. This treatment will be tested both on its own and in combination with other cancer-fighting drugs to see how safe and effective it is for patients with these cancers.

The purpose of the study is to understand how well MK-2870 works and how patients tolerate it. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor participants for any side effects and how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, researchers will keep track of how long the treatment works, how long patients live without the cancer getting worse, and overall survival rates. The study aims to provide valuable information that could lead to better treatment options for people with these types of cancers. The trial is expected to continue until 2026, with recruitment starting in 2024.

]]> Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer https://clinicaltrials.eu/trial/study-on-bi-907828-for-patients-with-advanced-biliary-tract-pancreatic-lung-or-bladder-cancer/ Wed, 29 Apr 2026 14:26:22 +0000 https://clinicaltrials.eu/trial/study-on-bi-907828-for-patients-with-advanced-biliary-tract-pancreatic-lung-or-bladder-cancer/ This clinical trial is focused on studying the effects of a new treatment called BI 907828 on certain types of cancer. The cancers being studied include biliary tract cancer, which affects the bile ducts, gallbladder, and ampulla of Vater; pancreatic cancer, specifically pancreatic ductal adenocarcinoma; lung cancer, specifically lung adenocarcinoma; and bladder cancer, specifically urothelial bladder cancer. These cancers are known to be locally advanced or have spread to other parts of the body, making them challenging to treat with standard therapies.

The purpose of this study is to evaluate how effective and safe BI 907828 is when used alone in treating these cancers. The study will involve patients who have specific genetic characteristics, such as MDM2 amplification and TP53 wild-type status, which are important for the treatment to potentially work. Participants will take the medication in the form of a film-coated tablet by mouth. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, patients will be closely observed to assess the treatment’s impact on their cancer and overall health. The study aims to gather information on how long the treatment can control the disease, how long patients live after starting the treatment, and any changes in their quality of life. This information will help determine if BI 907828 could be a beneficial treatment option for these types of cancer in the future.

]]> Study of pembrolizumab with gemcitabine and cisplatin as first treatment for patients with advanced or inoperable bile duct cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-gemcitabine-and-cisplatin-for-patients-with-advanced-biliary-tract-cancer/ Wed, 29 Apr 2026 14:26:00 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-gemcitabine-and-cisplatin-for-patients-with-advanced-biliary-tract-cancer/ This study focuses on Biliary Tract Carcinoma, a type of cancer that affects the bile ducts and gallbladder. The research evaluates the effectiveness of combining three medications: pembrolizumab (also known as KEYTRUDA), gemcitabine, and cisplatin in treating advanced or inoperable biliary tract cancer. Some participants will receive these medications, while others will receive gemcitabine and cisplatin with a placebo instead of pembrolizumab.

The purpose of this research is to determine if adding pembrolizumab to the standard treatment of gemcitabine and cisplatin helps patients live longer. The medications are given through intravenous infusion, which means they are administered directly into a vein. Pembrolizumab or placebo is given along with gemcitabine and cisplatin according to a specific schedule throughout the treatment period.

This is a double-blind study, which means neither the patients nor their doctors will know whether they are receiving pembrolizumab or placebo. The treatment will continue for several months, with regular medical check-ups to monitor the patient’s health and how well the treatment is working. The study team will track how the cancer responds to treatment and any side effects that may occur.

]]> Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer https://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-cisplatin-durvalumab-and-trastuzumab-for-patients-with-advanced-biliary-cancer/ Wed, 29 Apr 2026 14:25:34 +0000 https://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-cisplatin-durvalumab-and-trastuzumab-for-patients-with-advanced-biliary-cancer/ This clinical trial is focused on studying treatments for advanced biliary cancer, a type of cancer that affects the bile ducts. The trial aims to compare a personalized treatment approach using specific medications to the standard treatment currently used for this condition. The medications being studied include Cisplatin, Durvalumab (known as IMFINZI), Trastuzumab (known as Zercepac), Futibatinib, Niraparib (also known as MK-4827), Neratinib (known as Nerlynx), Binimetinib (known as Mektovi), Zanidatamab (known as JZP598), Encorafenib (known as Braftovi), and Ivosidenib. Some patients will receive a placebo as part of the study.

The purpose of the study is to determine if the personalized treatment approach is more effective in preventing the cancer from getting worse compared to the standard treatment. Participants will first receive four cycles of the standard treatment. After this, they will be randomly assigned to either continue with the standard treatment or switch to a personalized treatment based on the specific characteristics of their cancer. The study will monitor the participants’ health and the progression of their cancer over time.

Throughout the study, participants will undergo regular health assessments to track their response to the treatment. The study will last for several months, and participants will be closely monitored by healthcare professionals to ensure their safety and well-being. The ultimate goal is to find out if the personalized treatment can help patients live longer without their cancer progressing.

]]> Study on Cisplatin, Gemcitabine, and Paclitaxel Albumin-Bound for Patients with Resectable Biliary Tract Cancer at High Risk of Recurrence https://clinicaltrials.eu/trial/study-on-cisplatin-gemcitabine-and-paclitaxel-albumin-bound-for-patients-with-resectable-biliary-tract-cancer-at-high-risk-of-recurrence/ Wed, 29 Apr 2026 14:24:07 +0000 https://clinicaltrials.eu/trial/study-on-cisplatin-gemcitabine-and-paclitaxel-albumin-bound-for-patients-with-resectable-biliary-tract-cancer-at-high-risk-of-recurrence/ This clinical trial is focused on studying treatments for biliary tract cancers, which are cancers that occur in the bile ducts, gallbladder, and other parts of the biliary system. The study is comparing two approaches for patients with these cancers who are at high risk of the cancer coming back after surgery. One group of patients will receive a combination of medications called Cisplatin, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Bound as chemotherapy before surgery. The other group will have surgery right away without receiving these medications first. The purpose of the study is to see which approach is more effective in preventing the cancer from returning within 12 months.

Participants in the study will be randomly assigned to one of the two groups. Those receiving the chemotherapy will have the medications administered through an infusion, which means the drugs are given directly into the bloodstream through a vein. The chemotherapy treatment will last for a specific period before the surgery is performed. The study will monitor the patients’ health and progress over time to determine the effectiveness of the treatment. Some patients may receive a placebo as part of the study, which is a substance with no active medication, to help compare the results.

The study aims to provide valuable information on whether receiving chemotherapy before surgery can improve outcomes for patients with biliary tract cancers. By comparing the two groups, researchers hope to find the best approach to reduce the risk of cancer recurrence and improve the quality of life for patients. The study will continue to follow participants for a period to gather comprehensive data on the long-term effects and benefits of the treatments being tested.

]]>